Mykor MykoFoam — Mycelium Building Insulation Panels

Product · Building Envelope

Product · InnDex 28 · Evidence provided · High specification risk

Mycelium-based insulation panels grown from agricultural waste in 4 weeks; claims 35% cost advantage and carbon-negative lifecycle.

Mykor inoculates agricultural waste residues with fungal mycelium and cures composite panels over ~4 weeks using a low-energy process at its Portuguese facility. It targets interior insulation demand in the building envelope, positioning itself as a cost-competitive and bio-based alternative to natural-fibre and synthetic insulators. The product claims carbon-negative lifecycle and cost parity advantage, but lacks published independent thermal performance data, fire ratings, or named project deployments.

Mykor grows mycelium-bound panels from agricultural waste residues at its Portuguese facility over a four-week curing cycle, positioning the product as a carbon-negative, cost-competitive alternative to natural-fibre insulation in building envelopes, with a claimed 35% cost advantage and biodegradable end-of-life distinguishing it from persistent synthetic foams. A €4.6M Series A in May 2026 confirms investor conviction, but the product's compliance documentation is absent in a way that makes it currently unspecifiable: no published thermal conductivity (λ-value), no Euroclass fire rating, and no moisture absorption data mean a specifier cannot verify building code compliance or make an objective comparison to alternatives. Biological materials in building envelopes carry intrinsic risk that is not solved by a good growth process — moisture ingress, mould, and dimensional instability under real thermal cycling are well-documented failure modes in bio-based insulation, and the regulatory pathway for Euroclass fire classification of a novel mycelium composite in EU and UK markets has not been articulated. The carbon-negative lifecycle claim and the 35% cost advantage are both unvalidated by independent LCA or production-volume cost data; if feedstock costs or manufacturing complexity rises, these figures may not replicate at commercial scale or in different markets. MykoFoam belongs on the watch list for projects with a genuine mandate for bio-based, low-embodied-carbon materials; it cannot be specified until fire classification and thermal performance data are independently certified.

Strengths

• Low-embodied-energy manufacturing process (~4 weeks, minimal thermal input) vs. synthetic or expanded foam insulation
• Carbon-negative lifecycle claim addresses whole-life environmental impact concern in building envelope design
• 35% cost advantage over natural-fibre competitors (if validated) improves retrofit economics
• Agricultural waste valorization creates closed-loop feedstock model
• Biodegradable/compostable end-of-life vs. persistent synthetic foams

Considerations

• No published thermal conductivity (λ-value), fire rating (Euroclasses A1/B-s2,d0), or moisture absorption data — specifiers cannot currently verify compliance with building codes or compare objectively to alternatives (critical)
• Biological material inherently vulnerable to moisture ingress, mould growth, and biological decay if not protected by vapour barriers or kept dry — adds design/detailing burden and long-term failure risk in high-humidity zones (high)
• Pilot-scale production (one Portuguese facility) — manufacturing scalability, cost replication, and supply chain resilience unproven; 4-week curing time is slow vs. factory-made boards (high)
• Material performance (strength, durability, dimensional stability) under real building thermal cycles and mechanical loads not yet documented in peer-reviewed literature or third-party test reports (high)

Risks

• No named commercial building projects or performance data in use — cannot verify real-world thermal performance, settlement, or long-term integrity claims (critical)
• Fire safety classification unknown; mycelium composites may present untested smoke/toxicity profiles under fire conditions — regulatory approval path and Euroclassification timeline unclear (critical)
• Cost advantage claim (35% vs. natural fibre) is unvalidated; if production scales significantly or feedstock costs rise, margin may erode or claim may not replicate in different markets (moderate)
• Biological colonization/contamination during curing or in-service could introduce off-gassing, allergenic spores, or secondary organism growth if environmental controls or protective barriers fail (high)
• Limited independent sector validation despite €4.6M Series A (May 2026) — no third-party certifications (CE marking, building product standards) publicly evidenced; regulatory pathway in EU, UK, or North America not articulated (high)

Performance

• Cost vs natural-fibre alternatives: Up to 35% lower (company claim, unverified)
• CO₂ vs conventional insulation: 60% less (company claim, no EPD)
• Sound absorption at 1000Hz: ~75% (company estimate)
• Production growth timeline: Scale from pilot from H2 2026

Reality check

Funding and facility location confirmed via TheNextWeb. Thermal performance claims ('competitive with mineral wool') and cost advantage (35% vs natural-fibre) are stated but not independently verified. Carbon-negative lifecycle claim requires LCA publication — none found. No third-party fire, moisture, or durability testing disclosed. No named commercial projects, pilot buildings, or specification wins identified. Certification pathway mentioned but not detailed. Female founder noted in source but not verified as material differentiation for credibility assessment.

#mycelium_composite #bio_based_insulation #agricultural_waste #circular_material #interior_insulation

Source